Rinat Galiulin

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Nick Thatcher, Fred R. Hirsch, Alexander Luft et al. · The Lancet Oncology · 2015 · 472 citations · Full text

First-line Therapy, Medicine, Pathology +7

International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1

Giorgio V. Scagliotti, Ihor Vynnychenko, Keunchil Park et al. · Journal of Clinical Oncology · 2012 · 183 citations · Full text

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Matthew J. Matasar, Marcelo Capra, Muhıt Özcan et al. · The Lancet Oncology · 2021 · 132 citations · Full text

Lymphoid Neoplasia, Medicine, Pharmacology +7

A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).

Nick Thatcher, Fred R. Hirsch, Aleksandra Szczęsna et al. · Journal of Clinical Oncology · 2014 · 41 citations

Immunology, Pathology, First-line Treatment +18

An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).

Giorgio V. Scagliotti, Ihor Vynnychenko, Y. Ichinose et al. · Journal of Clinical Oncology · 2011 · 24 citations

Pathology, Pharmacotherapy, Metronomic Chemotherapy +18